Pharmacogenetic Considerations for Irinotecan Therapy
DOI:
https://doi.org/10.69734/1syww840Keywords:
irinotecan, Pharmacogenetic , personalized medicine, FOLFIRINOXAbstract
Pharmacogenetic testing provides a valuable tool for personalizing irinotecan therapy, which is often used to treat pancreatic cancer, as well as many others such as colorectal cancer. Genetic variability in Uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1), which contributes to the metabolism of irinotecan, has been shown to significantly influence the risk of experiencing severe toxicity. Emerging evidence has demonstrated assessing patients for genetic variation in UGT1A1 can help to minimize adverse effects and clinical guidelines for genotype-guided irinotecan dosing are available.
References
Rivory LP, Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther. 1995;68(2):269-296. doi:10.1016/0163-7258(95)02009-8
Hulshof EC, Deenen MJ, Nijenhuis M, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Eur J Hum Genet. 2023;31(9):982-987. doi:10.1038/s41431-022-01243-2
FDA. No Title. Table of Pharmacogenomic Biomarkers in Drug Labeling. Published 2020. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
Table of Pharmacogenetic Associations. Food and Drug Administration. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
Quaranta S, Thomas F. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics. Therapie. 2017;72(2):205-215. doi:10.1016/j.therap.2017.01.005
Recommendations for pharmacogenetic testing by AIOM-SIF working group. Available from: https://www.aiom.it/wp-content/uploads/2019/10/2019_Racc-analisi-farmacogenetiche_v26.3.2020.pdf. Accessed Date: December 10,2024.
Pharmacogenomics Working Party. European Medicine Association (EMA). Available online: https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/pharmacogenomics-working-party. Accessed date: December 10, 2024.
NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 5.2024. Available from: https://www.nccn.org/guidelines/category_1. Accessed date: December 10, 2024.
Barbarino JM, Haidar CE, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 2014;24(3):177-183. doi:10.1097/FPC.0000000000000024
Kanai M, Kijima K, Shirahata E, et al. Neonatal hyperbilirubinemia and the bilirubin uridine diphosphate-glucuronosyltransferase gene: the common -3263T > G mutation of phenobarbital response enhancer module is not associated with the neonatal hyperbilirubinemia in Japanese. Pediatr Int. 2005;47(2):137-141. doi:10.1111/j.1442-200x.2005.02030.x
Aono S, Adachi Y, Uyama E, et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert’s syndrome. Lancet (London, England). 1995;345(8955):958-959. doi:10.1016/s0140-6736(95)90702-5
Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333(18):1171-1175. doi:10.1056/NEJM199511023331802
Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369. doi:10.1002/cpt.269
Nelson RS, Seligson ND, Bottiglieri S, et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel). 2021;13(7). doi:10.3390/cancers13071566
Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27(16):2604-2614. doi:10.1200/JCO.2008.20.6300
Su Y-Y, Chiang N-J, Chang JS, et al. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO open. 2023;8(1):100746. doi:10.1016/j.esmoop.2022.100746
Denlinger CS, Blanchard R, Xu L, et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;65(1):97-105. doi:10.1007/s00280-009-1008-7
Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2(1):43-47. doi:10.1038/sj.tpj.6500072
de Jong FA, Kehrer DFS, Mathijssen RHJ, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist. 2006;11(8):944-954. doi:10.1634/theoncologist.11-8-944
Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004;44(8):854-860. doi:10.1177/0091270004267159
Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J. 2014;14(2):120-129. doi:10.1038/tpj.2013.10
Nguyen CTT, Nguyen TMT, Phung TH. Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients. Pharmacogenomics. 2024;25(10-11):469-477. doi:10.1080/14622416.2024.2385289
Yang Y, Zhou M, Hu M, et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis. Asia Pac J Clin Oncol. 2018;14(5):e479-e489. doi:10.1111/ajco.13028
Atasilp C, Biswas M, Jinda P, et al. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clin Transl Sci. 2022;15(7):1613-1633. doi:10.1111/cts.13277
Innocenti F, Schilsky RL, Ramírez J, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014;32(22):2328-2334. doi:10.1200/JCO.2014.55.2307
Tsai H-L, Huang C-W, Lin Y-W, et al. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Eur J Cancer. 2020;138:19-29. doi:10.1016/j.ejca.2020.05.031
Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(5):866-871. doi:10.1200/JCO.2009.23.6125
Toffoli G, Sharma MR, Marangon E, et al. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017;23(4):918-924. doi:10.1158/1078-0432.CCR-16-1012
Oki E, Kato T, Bando H, et al. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. Clin Colorectal Cancer. 2018;17(2):147-155. doi:10.1016/j.clcc.2018.01.011
Shirasu H, Todaka A, Omae K, et al. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer Sci. 2019;110(2):707-716. doi:10.1111/cas.13883
Keum J, Lee HS, Jo JH, et al. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Cancers (Basel). 2022;14(5). doi:10.3390/cancers14051244
Goetz MP, McKean HA, Reid JM, et al. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013;31(6):1559-1567. doi:10.1007/s10637-013-0034-9
Hulshof EC, de With M, de Man FM, et al. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022;162:148-157. doi:10.1016/j.ejca.2021.12.009
Akiyama Y, Fujita K, Nagashima F, et al. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2008;19(12):2089-2090. doi:10.1093/annonc/mdn645
Mathijssen RHJ, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res. 2003;9(9):3246-3253. http://www.ncbi.nlm.nih.gov/pubmed/12960109
Li M, Seiser EL, Baldwin RM, et al. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018;18(1):35-42. doi:10.1038/tpj.2016.75
Reizine N, Vokes EE, Liu P, et al. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020;12:1758835920974118. doi:10.1177/1758835920974118
Downloads
Published
Versions
- 2024-12-26 (3)
- 2024-12-26 (2)
- 2024-12-23 (1)
Issue
Section
License
Copyright (c) 2024 SMART-MD Journal of Precision Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal information